Article
Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy.
Breast (Edinburgh, Scotland) - 1 Dec 2018
de Vries Schultink Aurelia H M, Huitema Alwin D R, Beijnen Jos H
Abstract excerpt
Different strategies have been proposed to individualize tamoxifen treatment in order to improve recurrence-free survival in estrogen receptor (ER)-positive breast cancer. To date, the debate remains on which strategy should be used. The objective of this viewpoint is to highlight Therapeutic Drug Monitoring of endoxifen, the active tamoxifen metabolite, as the preferred methodology compared to CYP2D6 genotyping...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.